This inventor holds 30 USPTO granted patents and 7 published patent applications, plus 4 CIPO patents and 15 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Roche Palo Alto LLC, Hoffmann-La Roche Inc., Jn Therapeutics. Active years: 2009-2024.
Location History:
- Shangai, CN (2010)
- Shanghai, CN (2009 - 2019)
- Nanjing, CN (2010 - 2024)
Company Filing History:
21 out of 322 
6 out of 5,024 
1 out of 1 Years Active: 2009-2024
Areas of Expertise:
Title: Minmin Yang: Innovator in Pharmaceutical Chemistry
Introduction
Minmin Yang, based in Shanghai, China, is a prominent inventor with a remarkable portfolio of 29 patents to his name. His work primarily focuses on pharmaceutical innovations, specifically in the area of chemical compounds that target various diseases.
Latest Patents
Among his latest contributions to the field are the patents for substituted imidazo[1,2-A]pyridin-2-ylamine compounds. These compounds and the pharmaceutical compositions derived from them are designed to treat, prevent, or ameliorate symptoms of Janus kinase-mediated diseases. Additionally, Yang has patented methods for antagonizing P2X and P2Y receptors, showcasing his commitment to advancing therapeutic solutions for diseases that involve misregulation of these receptors.
Career Highlights
Minmin Yang has had a fruitful career with significant stints at renowned companies in the pharmaceutical industry, including Roche Palo Alto LLC and Hoffmann-La Roche Inc. His experience in these leading organizations has enabled him to hone his skills in drug development and innovation.
Collaborations
Throughout his professional journey, Yang has collaborated with notable industry colleagues, including Michael Patrick Dillon and Li Chen. These collaborations emphasize the importance of teamwork in the advancement of scientific research and the development of effective pharmaceutical solutions.
Conclusion
Minmin Yang continues to push the boundaries of pharmaceutical chemistry through his innovative work and patents. With a strong focus on targeting complex diseases, his contributions enrich the scientific community and hold promise for the future of healthcare.